Patients with lower-risk myelodysplastic syndromes (MDS) remain regular transfusions dependent, acquiring a secondary post-transfusion excess of iron, which is an indication for prescribing chelation therapy. This problem continues to be studied all over the world, in confirmation of that, there are around 40 sources of literature review are given in this article. The relevance of studying excess of iron and treatment of patients with lower-risk MDS acquires not so much a decrease in ferritin, as the problem of possible reduce of mortality, not related to the progression of MDS and improving the overall survival rate of this contingent. Such kind of researches in Uzbekistan were conducted only in patients with thalassemia. Therefore it’s needed to study this problem in patients with MDS.
Gritsaev, S.V.; Yusupova, Z.D.; Boymatova, N.Ah.; and Babadzhanova, Sh.D.
"COMPLEX PATHOGENETIC APPROACH OF IRON DEFICIENCY CORRECTION IN PATIENTS WITH LOW RISK MYELOPLASTIC SYNDROME,"
Central Asian Journal of Pediatrics: Vol. 2
, Article 28.
Available at: https://uzjournals.edu.uz/pediatrics/vol2/iss1/28